168 related articles for article (PubMed ID: 26091301)
21. T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness.
Downey JS; Attaf M; Moyle G; Gazzard B; Gotch F; Imami N
AIDS; 2011 Oct; 25(16):1981-6. PubMed ID: 21811141
[TBL] [Abstract][Full Text] [Related]
22. Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells.
Larsson M; Wilkens DT; Fonteneau JF; Beadle TJ; Merritt MJ; Kost RG; Haslett PA; Cu-Uvin S; Bhardwaj N; Nixon DF; Shacklett BL
AIDS; 2002 Jan; 16(2):171-80. PubMed ID: 11807300
[TBL] [Abstract][Full Text] [Related]
23. CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype.
Gillespie GM; Pinheiro S; Sayeid-Al-Jamee M; Alabi A; Kaye S; Sabally S; Sarge-Njie R; Njai H; Joof K; Jaye A; Whittle H; Rowland-Jones S; Dorrell L
Eur J Immunol; 2005 May; 35(5):1445-53. PubMed ID: 15832290
[TBL] [Abstract][Full Text] [Related]
24. Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use.
Camara M; Dieye TN; Seydi M; Diallo AA; Fall M; Diaw PA; Sow PS; Mboup S; Kestens L; Jennes W
J Infect Dis; 2010 Mar; 201(6):835-42. PubMed ID: 20136413
[TBL] [Abstract][Full Text] [Related]
25. Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.
Tomescu C; Seaton KE; Smith P; Taylor M; Tomaras GD; Metzger DS; Montaner LJ
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):264-73. PubMed ID: 25514793
[TBL] [Abstract][Full Text] [Related]
26. Deciphering the Role of Mucosal Immune Responses and the Cervicovaginal Microbiome in Resistance to HIV Infection in HIV-Exposed Seronegative (HESN) Women.
Munusamy Ponnan S; Thiruvengadam K; Tellapragada C; Ambikan AT; Narayanan A; Kathirvel S; Mathayan M; Shankar J; Rajaraman A; Afshan Amanulla M; Dinesha TR; Poongulali S; Saravanan S; Murugavel KG; Swaminathan S; Velu V; Shacklett B; Neogi U; Hanna LE
Microbiol Spectr; 2021 Oct; 9(2):e0047021. PubMed ID: 34704803
[TBL] [Abstract][Full Text] [Related]
27. Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals.
Kebba A; Kaleebu P; Rowland S; Ingram R; Whitworth J; Imami N; Gotch F
J Infect Dis; 2004 May; 189(9):1705-13. PubMed ID: 15116309
[TBL] [Abstract][Full Text] [Related]
28. Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals.
Furci L; Lopalco L; Loverro P; Sinnone M; Tambussi G; Lazzarin A; Lusso P
AIDS; 2002 May; 16(7):1003-8. PubMed ID: 11953466
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India.
Pallikkuth S; Wanchu A; Bhatnagar A; Sachdeva RK; Sharma M
Clin Vaccine Immunol; 2007 Sep; 14(9):1196-202. PubMed ID: 17823271
[TBL] [Abstract][Full Text] [Related]
30. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
[TBL] [Abstract][Full Text] [Related]
31. Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells.
Hladik F; Desbien A; Lang J; Wang L; Ding Y; Holte S; Wilson A; Xu Y; Moerbe M; Schmechel S; McElrath MJ
J Immunol; 2003 Sep; 171(5):2671-83. PubMed ID: 12928421
[TBL] [Abstract][Full Text] [Related]
32. [HIV-1 nef specific cytotoxic T lymphocyte responses in long-term nonprogressors and AIDS patients].
Zhang HW; Qiu ZF; Li TS
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1973-6. PubMed ID: 15730808
[TBL] [Abstract][Full Text] [Related]
33. Elevated Numbers of HIV-Specific Poly-Functional CD8
Munusamy Ponnan S; Thiruvengadam K; Kathirvel S; Shankar J; Rajaraman A; Mathaiyan M; Dinesha TR; Poongulali S; Saravanan S; Murugavel KG; Swaminathan S; Tripathy SP; Neogi U; Velu V; Hanna LE
Front Immunol; 2021; 12():638144. PubMed ID: 33889151
[TBL] [Abstract][Full Text] [Related]
34. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.
Keating SM; Bollinger RC; Quinn TC; Jackson JB; Carruth LM
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1067-79. PubMed ID: 12396458
[TBL] [Abstract][Full Text] [Related]
35. Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese.
Liu HW; Hong KX; Ma J; Yuan L; Liu S; Chen JP; Zhang YZ; Ruan YH; Xu JQ; Shao YM
Chin Med J (Engl); 2006 Oct; 119(19):1616-21. PubMed ID: 17042974
[TBL] [Abstract][Full Text] [Related]
36. HIV viral set point and host immune control in individuals with HIV-specific CD8+ T-cell responses prior to HIV acquisition.
Kaul R; MacDonald KS; Nagelkerke NJ; Kimani J; Fowke K; Ball TB; Luo M; Kariri A; Jaoko W; Moses S; Rowland-Jones S; Plummer FA
AIDS; 2010 Jun; 24(10):1449-54. PubMed ID: 20549840
[TBL] [Abstract][Full Text] [Related]
37. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
38. Mx2 expression is associated with reduced susceptibility to HIV infection in highly exposed HIV seronegative Kenyan sex workers.
Stein DR; Shaw SY; McKinnon LR; Abou M; McCorrister SJ; Westmacott GR; Fowke KR; Plummer FA; Ball TB
AIDS; 2015 Jan; 29(1):35-41. PubMed ID: 25562491
[TBL] [Abstract][Full Text] [Related]
39. Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons.
Schmechel SC; Russell N; Hladik F; Lang J; Wilson A; Ha R; Desbien A; McElrath MJ
Immunol Lett; 2001 Nov; 79(1-2):21-7. PubMed ID: 11595286
[TBL] [Abstract][Full Text] [Related]
40. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood.
Clerici M; Levin JM; Kessler HA; Harris A; Berzofsky JA; Landay AL; Shearer GM
JAMA; 1994 Jan; 271(1):42-6. PubMed ID: 8258885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
